The potential of precision medicine in gynaecologic cancers – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“ESMOGynae24: The combination of comprehensive genomic profiling and ranking genomic alterations using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

After discussion in a Molecular Tumour Board, 22 patients received molecularly guided treatment options showcasing the potential of precision medicine in gynaecologic cancers, where ESMO is showing its commitment to facilitating patients’ access to optimal cancer care.”

Source: ESMO/LinkedIn